A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid

American Journal of Surgery

Volumn 185, Issue 4, 2003, Pages 369-375

  Wilson, Samuel Eric ^a   Solomkin, Joseph S ^b   Le, Vu ^c   Cammarata, Sue K ^c   Bruss, Jon B ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c PFIZER INC   (United States)

Author keywords

Flucloxacillin; Linezolid; Oxacillin; Scoring system; Severity of illness; Skin infection; Soft tissue infection

Indexed keywords

LINEZOLID;

ANEMIA; ARTICLE; CLINICAL TRIAL; COMORBIDITY; DISEASE SEVERITY; HIGH RISK PATIENT; HUMAN; HYPONATREMIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SKIN INFECTION; SOFT TISSUE INFECTION; SURGICAL WOUND; TREATMENT FAILURE; UREA NITROGEN BLOOD LEVEL; VALIDATION PROCESS; WOUND INFECTION;

EID: 0037377123     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(02)01411-3     Document Type: Article

References (25)

1. Baker S.P., O'Neill B., Haddon W., Long W.B. The injury severity score a method for describing patients with multiple injuries and evaluating emergency care . J Trauma. 14:1974;187-196.
2. Knaus W.A., Zimmerman J.E., Wagner D.P., et al. APACHE-acute physiology and chronic health evaluation a physiologically based classification system . Crit Care Med. 9:1981;591-597.
3. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. APACHE II a severity of disease classification system . Crit Care Med. 13:1985;818-829.
4. Knaus W.A., Wagner D.P., Draper E.A., et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest. 100:1991;1619-1636.
5. Le Gall J.R., Lemeshow S., Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 270:1993;2957-2963.
6. Fine M.J., Auble T.E., Yealy D.M., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 336:1997;243-250.
7. Niederman M.S., Mandell L.A., Anzueto A., et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 163:2001;1730-1754.
8. Bosscha K., Reijnders K., Hulstaert P.F., et al. Prognostic scoring systems to predict outcome in peritonitis and intra-abdominal sepsis. Br J Surg. 84:1997;1532-1534.
9. Lewis R.T. Soft tissue infections. World J Surg. 22:1998;146-151.
10. Swaney S.M., Aoki H., Ganoza M.C., Shinabarger D.L. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother. 42:1998;3251-3255.
11. Daly J.S., Eliopoulos G.M., Willey S., Moellering R.C. Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob Agents Chemother. 32:1988;1341-1346.
12. Eliopoulos G.M., Wennersten C.B., Gold H.S., Moellering R.C. In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Antimicrob Agents Chemother. 40:1996;1745-1747.
13. Noskin G.A., Siddiqui F., Stosor V., et al. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother. 43:1999;2059-2062.
14. Zurenko G.E., Yagi B.H., Schaadt R.D., et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother. 40:1996;839-845.
15. Ford C.W., Hamel J.C., Wilson D.M., et al. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob Agents Chemother. 40:1996;1508-1513.
16. Stevens D.L., Smith L.G., Bruss J.B., et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 44:2000;3408-3413.
17. Mangano R, Zotti G, Voros D, Molinari M. Comparison of linezolid and flucloxacillin sodium in the treatment of complicated skin infections: analysis of European and South African patients in a phase III trial. Third International Meeting on the Therapy of Infections, Florence, Italy, December 4-6, 2000.
18. Wall D.B., de Virgilio C., Black S., Klein S.R. Objective criteria may assist in distinguishing necrotizing fasciitis from nonnecrotizing soft tissue infection. Am J Surg. 179:2000;17-21.
19. Gee T., Ellis R., Marshall G., et al. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother. 45:2001;1843-1846.
20. Bisno A.L., Stevens D.L. Streptococcal infections of skin and soft tissues. N Engl J Med. 334:1996;240-245.
21. Stevens D.L., Maier K.A., Mitten J.E. Effect of antibiotics on toxin production and viability of Clostridium perfringens. Antimicrob Agents Chemother. 31:1987;213-218.
22. Stevens D.L., Bryant A.E., Hackett S.P. Antibiotic effects on bacterial viability, toxin production, and host response. Clin Infect Dis. 20:(suppl 2):1995;S154-157.
23. Pessa M.E., Howard R.J. Necrotizing fasciitis. Surg Gynecol Obstet. 161:1985;357-361.
24. Kaul R., McGeer A., Low D.E., et al. Population-based surveillance for group A streptococcal necrotizing fasciitis clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal study . Am J Med. 103:1997;18-24.
25. Swartz M.N. Cellulitis and subcutaneous tissue infections. Mandell G.L., Bennett J.E., Dolin R. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 2000;1037-1057 Churchill Livingstone, Philadelphia.